Galectin Therapeutics Inc. GALT
Set alert
3.32 USD -0.20 -5.68%
At close · Oct 30
3.37 +0.05 +1.51%
After hours · Oct 30, 4:00 PM ET
3.27 Day range 3.54
2.08 52-week range 6.51
- YTD
- -20.19%
- 1 year
- -34.52%
- Open
- 3.52
- Prev close
- 3.52
- Mkt cap
- 334.82M
- Vol
- 174.75K
- Avg vol
- 294.60K
- EPS
- -0.43
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.27
- High
- 3.54
- Forward P/E
- -0.53
- Beta
- 0.63
- Short ratio
- 42.37
- Inst. own
- 15.77%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.51
- 200-d avg
- 2.64
- 1y target
- 11.00
2Y chart
Events in this range
- Nov 14, 2024Earnings: -0.18; estimate -0.2; surprise 10%
- Nov 15, 2024Rating: HC Wainwright & Co. · Buy → Buy
Signals (84)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 27, 2026 | 4 days ago |
| SMA: Bearish | Oct 23, 2026 | 1 week ago |
| SMA: Bearish | Oct 13, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 7, 2026 | 3 weeks ago |
| SMA: Bullish | Sep 18, 2026 | 1 month ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 10, 2026 | 1 month ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 14, 2026 | 2 months ago |
| SMA: Bearish | Jul 30, 2026 | 3 months ago |
| SMA: Bearish | Jul 22, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 16, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 14, 2026 | 3 months ago |
| RSI: Overbought | Jul 14, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 10, 2026 | 3 months ago |
| RSI: Overbought | Jul 2, 2026 | 4 months ago |
| SMA: Bullish | Jun 24, 2026 | 4 months ago |
| RSI: Overbought | Jun 23, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 11, 2026 | 4 months ago |
| SMA: Bullish | Jun 8, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 5, 2026 | 4 months ago |
| SMA: Bullish | May 21, 2026 | 5 months ago |
| MACD: Buy Signal | May 11, 2026 | 5 months ago |
| MACD: Sell Signal | May 8, 2026 | 5 months ago |
| MACD: Buy Signal | Apr 22, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 21, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 17, 2026 | 6 months ago |
| MACD: Sell Signal | Mar 19, 2026 | 7 months ago |
| SMA: Bearish | Mar 18, 2026 | 7 months ago |
| SMA: Bullish | Mar 16, 2026 | 7 months ago |
| SMA: Bearish | Mar 13, 2026 | 7 months ago |
| SMA: Bullish | Mar 12, 2026 | 7 months ago |
| SMA: Bearish | Mar 10, 2026 | 7 months ago |
| SMA: Bullish | Mar 9, 2026 | 7 months ago |
| MACD: Buy Signal | Jan 21, 2026 | 9 months ago |
| RSI: Oversold | Jan 16, 2026 | 9 months ago |
| SMA: Bearish | Jan 8, 2026 | 9 months ago |
| RSI: Oversold | Jan 8, 2026 | 9 months ago |
| SMA: Bullish | Jan 7, 2026 | 9 months ago |
| SMA: Bearish | Jan 6, 2026 | 9 months ago |
| RSI: Oversold | Jan 6, 2026 | 9 months ago |
| SMA: Bearish | Dec 19, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 19, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 12, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 10, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 8, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 5, 2025 | 11 months ago |
| MACD: Buy Signal | Dec 4, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 21, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 17, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 7, 2025 | 11 months ago |
| RSI: Overbought | Nov 3, 2025 | 12 months ago |
| MACD: Buy Signal | Oct 31, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 29, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 13, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 16, 2025 | 1 year ago |
| RSI: Overbought | Sep 8, 2025 | 1 year ago |
| RSI: Overbought | Sep 4, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 2, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 13, 2025 | 1 year ago |
| RSI: Overbought | Jul 29, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 14, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 2, 2025 | 1 year ago |
| RSI: Overbought | Jun 17, 2025 | 1 year ago |
| SMA: Bullish | Jun 12, 2025 | 1 year ago |
| SMA: Bearish | Jun 11, 2025 | 1 year ago |
| SMA: Bullish | Jun 10, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 3, 2025 | 1 year ago |
| MACD: Sell Signal | May 15, 2025 | 1 year ago |
| SMA: Bearish | May 8, 2025 | 1 year ago |
| SMA: Bullish | May 7, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 17, 2025 | 1 year ago |
| SMA: Bearish | Mar 31, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 26, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 25, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 18, 2025 | 1 year ago |
| RSI: Overbought | Mar 13, 2025 | 1 year ago |
| SMA: Bullish | Feb 18, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 7, 2025 | 1 year ago |
| RSI: Oversold | Dec 20, 2024 | 1 year ago |
| RSI: Oversold | Dec 9, 2024 | 1 year ago |
Key statistics
- Market cap
- 55.86M
- Enterprise value
- 241.35M
- Trailing P/E
- 0.00
- Forward P/E
- -0.53
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -0.73
- Beta
- 0.63
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -20.36M
- Total cash
- 25.60M
- Total debt
- 93.47M
- Return on equity
- 0.00%
- Shares outstanding
- 62.76M
- Short % of float
- 18.41%
- 50-day average
- 2.51
- 200-day average
- 2.64
Analyst view
Consensus: none
Price target (mean) 11.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
GALT Revenue — quarterly 0
GALT Net income — quarterly -9.11M
GALT EPS — quarterly -0.14
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.20 | -0.18 | +0.02 | +10.00% |
| Aug 13, 2024 | Jun 1, 2024 | -0.16 | -0.20 | -0.04 | -25.00% |
| May 15, 2024 | Mar 1, 2024 | -0.16 | -0.19 | -0.03 | -18.75% |
| Mar 29, 2024 | Dec 1, 2023 | -0.16 | -0.16 | 0.00 | 0.00% |
| Nov 13, 2023 | Sep 1, 2023 | -0.16 | -0.24 | -0.08 | -50.00% |
| Aug 14, 2023 | Jun 1, 2023 | -0.21 | -0.15 | +0.06 | +28.57% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 1, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 15, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| May 17, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About Galectin Therapeutics Inc.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- galectintherapeutics.com
News
- Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Reviewing Galectin Therapeutics (NASDAQ:GALT) & SQZ Biotechnologies (NYSE:SQZ)
- 20 stocks likely to lose money even if the bull market continues
- Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above 200-Day Moving Average – Here’s What Happened
- Galectin Therapeutics Q2 EPS $(0.14) Misses $(0.09) Estimate
- Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Galectin Therapeutics Converts ~$105.8M Of Debt Into ~34.4M Shares At Blended Average Conversion Price Of ~$3.07 Per Share
Your note
Sign in to keep a note on GALT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CZIRR JAMES C | Beneficial Owner of more than 10% of a Class of Security | Sale | Apr 22, 2024 | 0 |
| ELDRED KARY N. | Director | Purchase | Oct 22, 2024 | 54,638 |
| FREEMAN KEVIN D | Director | Purchase | Oct 16, 2024 | 132,832 |
| LEWIS JOEL | Chief Executive Officer | Purchase | Apr 23, 2024 | 0 |
| UIHLEIN RICHARD E | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jan 23, 2024 | 10,296,500 |
| ZORDANI RICHARD A. JR | Director | Purchase | Aug 22, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 3.40% | 2,134,205 | 1.90M | Sep 29, 2024 |
| Blackrock Inc. | 2.56% | 1,607,124 | 1.43M | Sep 29, 2024 |
| Osaic Holdings Inc | 1.88% | 1,182,095 | 1.05M | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.37% | 862,542 | 767.75K | Sep 29, 2024 |
| Commonwealth Equity Services, LLC | 0.77% | 483,264 | 430.15K | Sep 29, 2024 |
| Wealthspire Advisors, LLC | 0.63% | 398,374 | 354.59K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.99% | 1,247,562 | 1.11M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.07% | 670,160 | 596.51K | Sep 29, 2024 |
| iShares Russell 2000 ETF | 0.59% | 372,101 | 331.21K | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.44% | 278,527 | 247.92K | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.32% | 198,844 | 176.99K | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.17% | 107,352 | 95.55K | Oct 30, 2024 |